Inmune Bio, Inc. INMB
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026
Inmune Bio, Inc. (INMB) is a healthcare company listed in the US with a market value of about $33M. In fiscal year 2025 it had revenue of $50000 and net income of -$46M, a net margin of -91866.0%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 35% a year, a 5-year average ROIC of -65%.
About Inmune Bio
Inmune Bio is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2019. Revenue went from $11000 in 2020 to $50000 in 2025, growth of about 35.4% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 38% over three years (dilution for shareholders). It spends 41318% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50000 | $14000 | $155000 | $374000 | $181000 | $11000 | — | $0 | $0 |
| Net income | -$46M | -$42M | -$30M | -$27M | -$30M | -$12M | -$8M | -$12M | -$831486 |
| Free cash flow | -$24M | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-1.86 | $-2.11 | $-1.67 | $-1.52 | $-1.88 | $-1.01 | $-0.75 | $-1.43 | $-0.13 |
| Net margin | -91866.0% | -300600.0% | -19360.0% | -7299.2% | -16762.4% | -110000.0% | — | — | — |
| ROIC | -152.4% | -70.9% | -49.1% | -27.1% | -23.9% | -24.7% | -25.8% | -59.4% | -4.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Inmune Bio pay a dividend?
Not currently.
Is Inmune Bio a good stock to buy?
We do not give buy or sell advice. Inmune Bio scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.